Borderline leprosy

Known as: Borderline or dimorphous leprosy, Dimorphous Leprosies, Dimorphous Leprosy 
A form of LEPROSY in which there are clinical manifestations of both principal types (lepromatous and tuberculoid). The disease may shift toward one… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1945-2018
0102019452017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Musculoskeletal symptoms are not infrequent in leprosy and, when inaugural, may be difficult to differentiate from other… (More)
Is this relevant?
2004
2004
BACKGROUND Nerve damage is a common and disabling feature of leprosy, with unclear aetiology. It has been reported that the… (More)
Is this relevant?
2004
2004
The ILEP nerve function impairment and reaction research programme (INFIR 2) was a group of clinical trials conducted to identify… (More)
Is this relevant?
2002
2002
This is a retrospective study of 276 patients consisting of 157 active and 119 reactive patients of borderline leprosy. They were… (More)
Is this relevant?
2002
2002
A retrospective case note study was done of children below the age of 14 years who attended Dhoolpet Leprosy Research Centre… (More)
Is this relevant?
2002
2002
Out of 265 biopsies of leprosy patients received at the Experimental Pathology Laboratory of Schieffelin Leprosy Research and… (More)
Is this relevant?
1997
1997
Borderline leprosy patients often undergo acute changes in immune reactivity that manifest as reversal reaction (RR) in the… (More)
Is this relevant?
1994
1994
A whole blood assay is described to measure T cell mediated immune responses to leprosy and provide an alternative to the… (More)
Is this relevant?
1991
1991
Type-1 or reversal reactions are the major cause of nerve damage and disability in leprosy. We wished to determine whether there… (More)
Is this relevant?
1976
1976
68 patients were included in a prospective study of the treatment of borderline leprosy. 34 were treated with dapsone 5 mg daily… (More)
Is this relevant?